Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2935830 | 0.99 | S1PR1 (0.47) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL2935838 | 0.99 | S1PR1 (0.47) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL2935833 | 0.92 | S1PR1 (0.44) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL2930171 | 0.91 | S1PR1 (0.47) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL2934653 | 0.86 | S1PR1 (0.57) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2932163 | 0.84 | S1PR1 (0.66) | S1PR1S1PR5 | |
| SCHEMBL2934452 | 0.83 | S1PR1 (0.64) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL2935081 | 0.81 | S1PR1 (0.54) | S1PR1S1PR3 | |
| SCHEMBL2928814 | 0.80 | S1PR1 (0.53) | S1PR1S1PR3 | |
| SCHEMBL2936456 | 0.80 | S1PR1 (0.48) | S1PR1S1PR3S1PR5S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091950-B1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | claimed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | claimed |
| EP-2091950-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | claimed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | claimed |
| EP-2091950-B1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-2091950-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.